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We repurposed existing genotypes in DNA biobanks across the Electronic Medical Records and Genomics network to perform a
genome-wide association study for primary hypothyroidism, the most common thyroid disease. Electronic selection algorithms incor-
porating billing codes, laboratory values, text queries, and medication records identified 1317 cases and 5053 controls of European
ancestry within five electronic medical records (EMRs); the algorithms’ positive predictive values were 92.4% and 98.5% for cases
and controls, respectively. Four single-nucleotide polymorphisms (SNPs) in linkage disequilibrium at 9q22 near FOXE1 were associated
with hypothyroidism at genome-wide significance, the strongest being rs7850258 (odds ratio [OR] 0.74, p ¼ 3.96 3 109). This
association was replicated in a set of 263 cases and 1616 controls (OR ¼ 0.60, p ¼ 5.7 3 106). A phenome-wide association study
(PheWAS) that was performed on this locus with 13,617 individuals and more than 200,000 patient-years of billing data identified
associations with additional phenotypes: thyroiditis (OR ¼ 0.58, p ¼ 1.4 3 105), nodular (OR ¼ 0.76, p ¼ 3.1 3 105) and multi-
nodular (OR ¼ 0.69, p ¼ 3.9 3 105) goiters, and thyrotoxicosis (OR ¼ 0.76, p ¼ 1.5 3 103), but not Graves disease (OR ¼ 1.03,
p ¼ 0.82). Thyroid cancer, previously associated with this locus, was not significantly associated in the PheWAS (OR ¼ 1.29, p ¼
0.09). The strongest association in the PheWAS was hypothyroidism (OR ¼ 0.76, p ¼ 2.7 3 1013), which had an odds ratio that
was nearly identical to that of the curated case-control population in the primary analysis, providing further validation of the PheWAS
method. Our findings indicate that EMR-linked genomic data could allow discovery of genes associated with many diseases without
additional genotyping cost.Introduction
Since 2005, more than 900 genome-wide association
studies (GWASs) have identified genomic variants associ-
ated with more than 200 diseases and traits.1 Although
genotyping costs are decreasing, GWASs targeting a single
disease or trait are expensive, and recruitment of the neces-
sary number of patients can be challenging. Recently, elec-
tronic medical record (EMR)-linked DNA biobanks have
allowed researchers to study the genetic basis of disease
by using phenotypes derived solely from information con-
tained within the EMR.2–8 Most EMRs contain a dense
longitudinal record of a patient’s health conditions, the
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genotyping cost because patients often have more than
one clinically apparent disease. In this study, we explored
the hypothesis that genetic data from five previously con-
ducted EMR-based GWASs could be reused in a study of
a different phenotype of broad public health importance,
primary hypothyroidism (PH).
PH is the most common thyroid disorder; it affects
1%–5% of the population,9 and up to 12% of the elderly
express subclinical hypothyroidism.10 The majority of
cases result from chronic lymphocytic thyroiditis, or
Hashimoto thyroiditis (HT [MIM 140300]). Treatment
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Table 1. Evaluation of Primary Hypothyroidism Algorithm at the Five eMERGE Sites
Site Primary Phenotype Total Genotyped Subjects
Primary Hypothyroidism
Cases Controls Case PPV (%) Control PPV (%)
Group Health dementia 2532 397 1,160 98 100
Marshfield cataracts 4113 514 1,187 91 100
Mayo Clinic peripheral arterial disease 3043 233 1,884 82 96
Northwestern type 2 diabetes 1217 92 470 98 100
Vanderbilt normal cardiac conduction 2712 81 352 98 100
All sites 13,617 1317 5053 92.4a 98.5a
Genotype counts represent all subjects who were found by the hypothyroidism algorithms at each site and who were genotyped. Counts are limited to those
classified as ‘‘white’’ in the electronic medical record of each site. PPV ¼ positive predictive value.
a Average weighted for number of samples contributed to the total.monitoring of serum hormone levels. A number of rare
mutations have been shown to result in congenital hy-
pothyroidism, which is readily detectible through new-
born screening. These mutations can cause central hypo-
thyroidism (e.g., TSHB [MIM 188540]) or primary
hypothyroidism due to thyroid dysgenesis (e.g., TSHR
[MIM 603372]), alterations in thyroid transcription factors
(NKX2-1 [MIM 600635], FOXE1 [MIM 602617], and PAX8
[MIM 167415]), or dyshormonogenesis (NIS [MIM
601843], TG [MIM 188450], DUOX2 [MIM 606759],
DUOXA2 [MIM 612772], SLC26A4 [MIM 605646], and
DEHAL1[MIM 612025]).11–13 There is evidence of a genetic
component in autoimmune thyroid disease, including
PH;14,15 candidate-gene analysis and linkage studies16–19
suggest that loci contributing to the pathogenesis of PH
include CTLA4 (MIM 123890), PTPN22 (MIM 600716),
and the thyroglobulin (TG) gene. A GWAS of levels of
thyroid-stimulating hormone (TSH) in euthyroid individ-
uals has identified associations at 1p36.13,20 PDE8B21,22
(MIM 603390). and to a lesser degree, FOXE1.22,23
Implementation of EMRs can lead to a higher quality of
care, reduced cost, and improved adherence to guide-
lines.24–26 More recently, investigators have used EMRs
as a longitudinal resource for clinical and genomic re-
search.27 Significant challenges inherent in EMR-based
research include the accurate identification of cases and
controls from a data source that was not designed for
such a task. Methods of achieving high precision have
been developed and include cohort-selection algorithms
that identify subjects via a combination of billing codes,
records of medication prescription, laboratory or report
data, and use of informatics techniques such as natural
language processing to search for biomedical concepts in
unstructured clinical documentation.2,28,29 The portability
of such algorithms from one EMR system to another has
not been systematically evaluated and remains a potential
obstacle to secondary use of EMR data,30 a goal for the
recently released Meaningful Use criteria of the Health
Information Technology for Economic and Clinical Health
(HITECH) Act.530 The American Journal of Human Genetics 89, 529–542, OctoberWe sought to develop and implement a transportable
EMR-based algorithm to identify hypothyroidism cases
and controls. This study was performed in the Electronic
Medical Records and Genomics (eMERGE) Network, a
project that is sponsored by the National Human Genome
Research Institute and which involves five institutions
(Group Health Cooperative [GHC], Marshfield Clinic
[MFC], Mayo Clinic [MC], Northwestern University [NU],
and Vanderbilt University Medical Center [VU]) that
each have DNA biorepositories linked to their EMRs.3
Using genotype data derived from five prior GWASs per-
formed in five institutions, we conducted a GWAS to
identify genetic variants associated with PH. We then per-
formed a phenome-wide association study (PheWAS) on a
single-nucleotide polymorphism (SNP) associated with PH
to investigate the pleiotropy of this region. The PheWAS
method uses custom case and control definitions to
perform an unbiased scan of diseases represented in billing
codes accrued in the medical record; we have previously
demonstrated its validity through rediscovery of known
associations.4Subjects and Methods
eMERGE Network Sites
As of mid-2011, the eMERGE Network consisted of five institu-
tions (noted above) that each had DNA biorepositories linked to
their EMRs. Each EMR is linked to a DNA biobank. Details of these
biobanks have been published elsewhere.31,32 Each site has inves-
tigated at least one primary phenotype (Table 1) by performing
a GWAS after implementing and validating computer selection
logic to identify cases and controls from available EMR data. After
genotyping for these primary GWASswas complete, each site iden-
tified individuals with the network-wide phenotype PH from
within their genotyped population.
Five different EMR systems are used across eMERGE; three
sites (MFC, MC, and VU) use custom-developed EMR systems.
NU and GHC use EpicCare (Epic Systems Corporation, Verona,
WI). NU also uses Cerner PowerChart (Cerner Corporation,
Kansas City, MO). Each eMERGE site maintains research data7, 2011
warehouses to make EMR data accessible for clinical and genetic
research. Details of these systems have been published previ-
ously.3,31–33Evaluation and Development of Phenotype-Selection
Logic
The algorithm identifying cases and controls for PH was initially
created and iteratively refined at VU and then deployed at the
other four eMERGE sites. At VU, two physicians not associated
with algorithm development reviewed algorithm results with
access to the entire deidentified clinical records of individuals
meeting selection criteria. The results of the manual classification
were then used for improving the algorithms, and the procedure
was iterated until the positive predictive value reached the predes-
ignated target of R 95% for a random selection of unreviewed
algorithm-determined cases and controls.
The final algorithm required the presence of a thyroid replace-
ment medication for at least three months and at least one
International Classification of Disease, 9th edition code for
hypothyroidism, or abnormal thyroid function study, defined
as a study showing the laboratory value of thyroid stimulating
hormone (TSH) to be greater than 5 mIU/ml or showing the
laboratory value of abnormal free thyroxine (FT4) to be less
than 0.5 ng/dl. Secondary causes of hypothyroidism (e.g., post-
surgical hypothyroidism or medication-induced hypothy-
roidism) and other thyroid conditions (e.g., Graves disease
[GRD; MIM 275000], pregnancy-related hypothyroidism, or
thyroid cancer) were excluded by queries for medications,
billing codes, and radiology tests (so that contrast exposure
was excluded). Control subjects had at least one normal TSH
value (defined as between 0.5 and 5 mIU/ml) and had no occur-
rences of hypothyroidism billing codes, abnormal thyroid func-
tion tests, or thyroid replacement medications. Both cases and
controls excluded patients who had received medications po-
tentially altering thyroid function (such medications include
phenytoin, lithium, methimazole, and propylthiouracil). The
complete description of the final algorithm is available online
(see Web Resources). So that algorithm accuracy could be
determined, a randomly selected subset of cases and controls
was manually reviewed at each site by trained chart abstractors
or physicians, each of whom was blinded to the algorithm’s case
or control determination and had full access to the EMR data.
The review included a total of 300 cases and 300 controls.
Reviewers were instructed to mark as false positives individuals
designated as having subclinical hypothyroidism only and not
overt hypothyroidism.Genotyping
Genotyping was performed at the Center for Genotyping and
Analysis at the Broad Institute (two sites) and the Center for In-
herited Disease Research at Johns Hopkins University (three sites)
with the Human660W-Quadv1_A BeadChip, consisting of
561,490 SNPs and 95,876 intensity-only probes on a total of
13,617 subjects of European American ancestry, as designated in
the EMRs.
Data were cleaned with the quality-control (QC) pipeline
developed by the eMERGE Genomics Working Group.34 This
process includes evaluation of sample and marker call rate,
gender mismatch and anomalies, duplicate and HapMap concor-
dance, batch effects, Hardy-Weinberg equilibrium (HWE), sample
relatedness, and population stratification (implemented withThe AmericSTRUCTURE35 and EIGENSTRAT36). Relatedness was determined
on the basis of identity by descent (IBD) estimates generated
from the genome-wide genotype data in PLINK. All study sites
had individuals with an IBD estimate greater than 0.0625. We
also identified two inter-site related pairs from Mayo and Marsh-
field. In all cases of suspected relatedness, one individual from
each related pair and the child from identified trios were removed
from the analysis.
After QC, 522,164 SNPs were used for analysis on the basis of the
following QC criteria: SNP call rate> 99%, sample call rate> 99%,
minor allele frequency > 0.01, 99.99% concordance rate in dupli-
cates, unrelated samples only, and individuals of European
descent only (determination of European descent was based on
STRUCTURE analysis showing a >90% probability of being in
the CEU [Utah residents with ancestry from northern and western
Europe] cluster).We flagged all markers with HWE p< 13 104 for
further evaluation after analysis with standard criteria.34 The QC
and data analysis were performed with a combination of
PLINK,37 PLATO,38 and the R statistical package.Statistical Analysis
We evaluated the positive predictive value of case and control
determination for the automated algorithm. The positive pre-
dictive value was calculated as the number of true positive cases
(or controls), as determined by human expert review, divided
by the total number of cases (or controls) selected by the
algorithm.
Genetic analyses were limited to subjects of European American
ancestry (as determined by genetic ancestry) given the relatively
few individuals identified not to be of European descent (28 cases
and 146 controls). Single-locus tests of association were per-
formed via logistic regression in PLINK under the assumption of
an additive genetic model. The model was adjusted for birth
decade, sex, and site of ascertainment. Birth decade was chosen
instead of age of diagnosis because the latter is usually not avail-
able within EMR records and the former also allows adjustment
for possible differences in iodine supplementation over time. A
second model included birth decade, sex, site of ascertainment,
and the first principal component from EIGENSTRAT. The
genomic inflation factor for data in both models was 1.00.
Linkage disequilibrium was calculated and plotted with Locus-
Zoom.39 Tests of heterogeneity were performed with METAL.40
Analyses involving 1000 genomes data were carried out with
SNP Annotation and Proxy Search (SNAP) in the CEU population
panel.41
In addition to an unmatched analysis, we performed a genome-
wide association study of cases matched to controls.
In the matched analysis, controls were matched to cases by site,
sex, genotypic ancestry designation, and birth decade. We used
principal components one and two to match by genetic ancestry
with EIGENSTRAT; these values were allowed to vary slightly
between matches. To increase the number of controls matched
to cases, additional controls were added if the birth decade was
within one decade. For unrelated cases and controls, the
control-to-case matching ratio was at least 3:1. Cases were strati-
fied with their related controls, where appropriate, and matched
with additional nonrelated controls, when necessary, so that a
3:1 control-to-case ratio was achieved. Conditional logistic regres-
sion was performed for each SNP under the assumption of an
additive genetic model adjusted for birth decade and two prin-
cipal components.an Journal of Human Genetics 89, 529–542, October 7, 2011 531
Replication
Variants reaching genome-wide significance (p < 5 3 108) in
the discovery set were tested for association with PH in the
Mayo Genome Consortia (MayoGC), which includes Mayo
Clinic patients with both EMR and GWAS data derived from
prior studies on Illumina HumanHap550, Human610-Quad,
and Human660W-Quad platforms. Currently, the cohort
includes 6508 patients from three studies, the eMERGE periph-
eral arterial disease cases and controls, case and control patients
from a study of venous thromboembolism, and control patients
from a study of pancreatic cancer.42,43 Participants in the venous
thromboembolism study were genotyped with the Illumina
Human660W-Quad platform. Participants in the pancreatic
cancer study were genotyped with Illumina HumanHap550
and the Human 610-Quad chips. The PH algorithm was used
for identification of cases and controls from the non-eMERGE
subjects (n ¼ 3110). The top associations in the initial GWAS
were analyzed in the replication set via PLINK with logistic
regression under the assumption of an additive genetic model
adjusted for age and sex. MayoGC samples used for the replica-
tion analysis had distinct medical-record numbers from the
primary analysis, and IBD analysis within PLINK was used for
removal of any first-degree relatives (or twins or replicate
samples) of those individuals used within the primary eMERGE
analysis.Phenome-wide Association Study
After defining a region of interest in GWAS, we used all individ-
uals of European Ancestry in the eMERGE data set (N ¼ 13,617)
to investigate for possible pleiotropy due to this locus. To define
diseases, we queried all International Classification of Disease
(ICD), 9th edition, codes from the respective EMRs from the five
eMERGE sites. The PheWAS software uses these ICD codes to
classify each person as having one of 957 possible clinical pheno-
types (typically representing diseases). Each phenotype is treated
independently such that one person can have both the general
diagnosis of hypothyroidism as well as the specific diagnosis of
Hashimoto’s thyroiditis, presumably as the cause of their hypo-
thyroidism, if both are supported by the individual’s billing
record. For each disease, the PheWAS code defines relevant
control groups for each disease or finding, such that patients
with related diseases do not serve as controls for that disease
(e.g., a patient with psoriatic arthritis cannot serve as a control
for an analysis of rheumatoid arthritis). Analysis of each pheno-
type then proceeds using a pairwise analysis of all case and con-
trol groups for each SNP. We have observed that positive predic-
tive values increase when codes are present more than once in
the EMR, and here we required each case to have at least two
ICD codes in a PheWAS case group. We also did not analyze
phenotypes occurring in less than 20 patients (a prevalence of
0.15% in the data set). Controls were excluded if they had any
ICD codes in the PheWAS control exclusion ranges. After genera-
tion of case and control groups for each of the PheWAS pheno-
types, association analyses were performed with PLINK using
logistic regression adjusted for age, sex, and the first three prin-
cipal component analyses as calculated by EIGENSTRAT. To deter-
mine if PheWAS-detected disease associations were the result of
co-occurrence with hypothyroidism or a result of pleiotropy, we
then performed a PheWAS adjusted for diagnosis of hypothy-
roidism (defined by PheWAS code) as well as age, sex, and the first
three principal components.532 The American Journal of Human Genetics 89, 529–542, OctoberResults
Identification of subjects with Primary
Hypothyroidism
Table 1 presents the positive predictive value of the PH
phenotype algorithm at each of the five sites. A total of
13,617 subjects of European American ancestry were gen-
otyped for one of five primary eMERGE GWAS. The PH
algorithm identified 1,317 cases and 5,053 controls from
these samples. The remaining 7,247 individuals with
GWAS data across eMERGE were excluded because either
they met an exclusion criterion (e.g., on medications
such as amiodarone) or there was insufficient evidence
that they qualified as a control (e.g., lacking a TSH labora-
tory test or insufficient visit data). The average positive
predictive value, weighted by site sample size, was
92.4% for cases and 98.5% for controls. Positive predictive
values exceeded 90% for controls at all sites and for cases
in four of five sites. Cases were predominantly women
(73%) with median birth decade in the 1930s (Table 2).
All patient populations averaged more than a decade of
data within their EMRs. Figure S1 presents a schematic
of the algorithm.Genome-wide Analysis for Primary Hypothyroidism
The analysis identified four SNPs associated with hypo-
thyroidism at genome-wide significance after adjustment
for birth decade, sex, and study site: rs7850258,
rs965513, rs925489, and rs10759944 (Figure 1, Table 3,
Table S1). The minor alleles of all four SNPs are underrep-
resented among cases compared with controls at p <
8.2x109 and odds ratio (OR) 0.74 (95% confidence
interval 0.67-0.82). Analysis including the first principal
component did not alter the results. The four SNPs
located on chromosome 9 are in strong pair-wise linkage
disequilibrium (r2 > 0.98) with one another and 58-71 kb
from the nearest gene, FOXE1 (Figure 2). Analysis of
the pilot low coverage CEU data from 1000 genomes
found the four FOXE1 SNPs were not in linkage disequi-
librium (r2 > 0.80) with any coding region variants
(Figure S2).
To further investigate these genome-wide significant
results, we examined the tests of association within each
of the five sites. All four SNPs near FOXE1 were associated
with PH at p < 0.03 with similar effect sizes and direction
(OR 0.60-0.81, Table 4). The associations with PH were
strongest within the Marshfield Clinic Personalized Medi-
cine Research Project set, which had the largest case
sample size (n ¼ 514) among the study sites. There was
no evidence of heterogeneity across the study sites for
these four SNPs (p ¼ 0.9).
The replication population contained 263 cases and
1616 controls (Table 2). Analysis of the four genome-
wide significant variants near FOXE1 replicated the most
significant findings in the discovery data set with p <
1.1x105 (Table 4).7, 2011
Table 2. Characteristics of Hypothyroidism Cases and Controls
Primary Analysis Replication Set
Cases (n ¼ 1317) Controls (n ¼ 5053) Non-TSH Controls (n ¼ 5632) Cases (n ¼ 263) Controls (n ¼ 1616)
Median birth decade 1930 1930 1940 1930 1940
Age (yr)a 68.7 5 14.0 60.7 5 12.5 52.9 5 14.6 58.9 5 14.2 53.9 5 13.5
Female (%) 73.0 48.3 43.8 78.7 43.9
Follow-up (yr)b 19.3 5 9.4 15.5 5 9.5 13.0 5 11.0 11.9 5 4.9 10.1 5 5.6
Plus-minus values are mean5 SD.
a Age is calculated as the first age matching case definition (e.g., a qualifying billing code, laboratory value, or medication) or, for controls, first billing code.
b Follow-up entries were calculated as the number of years the patients was observed by billing codes.To assess the possibility of ascertainment bias, i.e., the
hypothesis that the physician ordering of a TSH labora-
tory test may bias toward patients with other autoim-
mune diseases, we also compared the PH cases to
patients who had no evidence of thyroid disease or
thyroid-active medications, but did not have TSH testing
performed (‘‘non-TSH controls’’; n ¼ 5,643 of the 7,247
patients excluded from the primary analysis). GWAS,
adjusted for age and sex, of PH cases to non-TSH controls
revealed results consistent in direction and magnitude to
those of our primary analysis. Results are presented in
Table 3 and Figure S3. The top four associated SNPs
were identical between both analyses and also reached
genome-wide significance (rs7850258, OR ¼ 0.74, p ¼
8.2x109). These data argue against a role for ascertain-
ment bias.
In addition to the genome-wide significant association
identified for SNPs along chromosome 9 near FOXE1, we
also identified several SNPs in the same chromosomeFigure 1. Genome-wide Association Analysis of Individuals with P
SNP tests of association (logistic regression) under the assumption of
site; the tests incorporated 522,164 SNPs. The red horizontal line ind
The Americassociated with PH near genome-wide significance.
Specifically, SNPs rs4979402, rs4979397, rs1408528,
and rs1535971 are associated with PH at p < 3.7x106
(Table 3) and are located in DFNB31 [MIM 607928].
DFNB31 is ~16.6Mb from FOXE1 and not in linkage
disequilibrium with the FOXE1 variants identified in
this study (r2 < 3x104); thus, these associations poten-
tially represent an independent locus associated with PH.
However, these regions were not as strongly associated
with hypothyroidism when compared with the non-
TSH control group. The analysis to non-TSH controls
identified additional areas of possible significance near
PVT1 [MIM 165140] (rs4733792), near TBL1X [MIM
300196] (rs17280788), and within CCBE1 [MIM
612753] (rs1791303) (Table 3). A genome-wide analysis
conditioned on rs925489 demonstrated that each of
the loci in Table 3 are independent of the FOXE1 vari-
ants with similar P values and effects as those presented
in Table 3.rimary Hypothyroidism versus Controls
an additive genetic model adjusted for sex, birth decade, and study
icates p ¼ 5 3 108, the threshold for genome-wide significance.
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Table 3. SNPs Associated with Hypothyroidism at p < 106 with Either Primary Controls or Non-TSH Controls
SNP Chromosome Position Minor Allele Nearest Gene
Minor Allele Frequency Cases versus ontrols Cases versus Non-TSH Controls
Case Controls Non-TSH Controls OR (95% CI) p Value OR (95% CI) p Value
rs7850258 9 99588834 A FOXE1 0.285 0.348 0.3452 0.74 (0.67–0. ) 3.96 3 109 0.74 (0.67–0.82) 8.17 3 109
rs965513 9 99595930 A FOXE1 0.286 0.348 0.3456 0.74 (0.67–0. ) 4.19 3 109 0.74 (0.67–0.82) 1.15 3 108
rs925489 9 99586421 C FOXE1 0.286 0.348 0.3452 0.74 (0.67–0. ) 4.68 3 109 0.74 (0.67–0.82) 1.17 3 108
rs10759944 9 99596793 A FOXE1 0.286 0.347 0.3445 0.75 (0.68-0.8 ) 8.19 3 109 0.74 (0.67–0.82) 1.50 3 108
rs4979402 9 116262496 G DFNB31 0.288 0.247 0.2518 1.29 (1.16–1. ) 1.23 3 106 1.17 (1.05–1.30) 0.0035
rs4979397 9 116259709 T DFNB31 0.286 0.246 0.2500 1.28 (1.16–1. ) 1.91 3 106 1.17 (1.06–1.31) 0.0033
rs1877432 9 99583701 A 9q22.3; near FOXE1 0.437 0.382 0.3885 1.25 (1.14–1. ) 1.99 3 106 1.28 (1.16–1.41) 4.29 3 107
rs1408528 9 116260594 C DFNB31 0.286 0.246 0.2507 1.28 (1.16–1. ) 2.07 3 106 1.17 (1.05–1.30) 0.0039
rs17827152 4 55173443 A 4q12; closest to KIT 0.263 0.219 0.2348 1.28 (1.15–1. ) 3.20 3 106 1.16 (1.04–1.29) 0.0084
rs1535971 9 116269221 T DFNB31 0.299 0.260 0.2629 1.27 (1.15-1.4 ) 3.65 3 106 1.17 (1.05–1.30) 0.0035
rs17043990 3 72963160 C SHQ1 0.0091 0.0024 0.0050 3.71 (2.08–6. ) 8.34 3 106 2.47 (1.44–4.25) 0.0011
rs4733792 8 128909458 T PVT1 0.4445 0.4077 0.3884 1.18 (1.08,1.3 ) 2.35 3 104 1.26 (1.14–1.39) 2.40x106
rs4733789 8 128903585 C PVT1 0.4461 0.4112 0.391 1.17 (1.07, 1. ) 5.51 3 104 1.26 (1.14–1.38) 3.01x106
rs17280788 X 9638573 T TBL1X 0.2612 0.2382 0.2133 1.14 (1.02–1. ) 0.019 1.35 (1.20–1.52) 9.94x107
rs1791303 18 55606206 T CCBE1 0.3651 0.4068 0.4111 0.83 (0.75, 0. ) 6.70 3 104 0.79 (0.72–0.87) 2.13x106
rs4940904 18 55606041 T CCBE1 0.3662 0.4071 0.4112 0.83 (0.76,0.9 ) 1.10 3 104 0.79 (0.72–0.88) 2.93x106
Analyses performed with logistic regression adjusted for birth decade, sex, and site of ascertainment. DFNB31 SNPs are in the gene. FOXE1 SNPs are from 5 –71 kb to the gene. The DIRAS2 SNP is in the gene. SHQ1 (MIM
602322) SNPs are in the gene.
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Figure 2. Regional Associations Near FOXE1The matched GWAS used 1314 cases and 3150 controls. Of
the 4464 subjects, 4185 (94%) were unrelated. The results
of the matched analysis were essentially identical to the
primary analysis except that significance levels tended to
be slightly lower (p < 2.6x108 for the top association,
Figures S4 and S5, Tables S2–S4), likely due to reduced
sample size.Phenome-wide association study of rs965513
Once associations with PH were established, we conducted
a PheWAS on rs965513 near FOXE1 to investigate for
other phenotypes potentially associated with this locus.
We selected rs965513 because it was strongly associated
with PH in our analysis and had also previously been
associated with an increased risk of thyroid cancer in
individuals of European descent.23,44 For this analysis, we
combined all self-identified European American individ-
uals from the five eMERGE sites (n ¼ 13,617). Subjects
had a total of 5,964,605 billing codes accrued over a total
of 217,619 patient-years. A total of 866 phenotypes from
more than 20 cases were analyzed, yielding a Bonferroni
correction of p ¼ 0.05/866 ¼ 5.8 3 105; this correction
is probably overly stringent given that many phenotypes
are related to each other. Figure 3 and Table 5 show pheno-
types associated with rs965513, which included acquired
hypothyroidism (OR ¼ 0.76, p ¼ 2.7 3 1013), thyroiditis
(OR ¼ 0.58, p ¼ 1.4 3 105), nodular (OR ¼
0.76, p ¼ 3.1 3 105), and multinodular (OR ¼ 0.69,
p ¼ 3.9 3 105) goiters, nutritional deficiency anemias
(OR ¼ 1.41, p ¼ 3.7 3 105), and thyrotoxicosis (OR ¼
0.76, p ¼ 1.5 3 103). The locus was also associated with
chronic lymphocytic thyroiditis (OR ¼ 0.58, p ¼ 2.5 3
104), a subset of thyroiditis, the most common cause of
PH. However, Graves disease (an autoimmune cause of
hyperthyroidism and one of the major etiologies of thyro-
toxicosis) was not associated with this locus (OR ¼ 1.03,
p ¼ 0.82). Associations with thyroid cancer, the previously
reported association, trended toward significance in this
analysis (OR ¼ 1.29, p ¼ 0.09), although only 96 cases
were present in this data set. However, rs965513 wasThe American Journal of Humweakly associated with other malignancies:
lymphoid tumors, including lymphosar-
coma and reticulosarcoma (n ¼ 130, OR ¼
1.35, p ¼ 0.02), salivary gland cancers
(n ¼ 22, OR ¼ 1.97, p ¼ 0.025), and eye
cancers (n ¼ 20, OR ¼ 1.97, p ¼ 0.03). The
PheWAS analysis adjusted for hypothy-
roidism status demonstrated more-signifi-
cant associations with nutritional-defi-ciency anemia, pernicious anemia, atrial flutter, and
thyroid cancer. Association with thyroid-related pheno-
types, such as goiters and thyroiditis, were weaker; many
of these also result in PH. Indeed, 80% of the individuals
with Hashimoto thyroiditis and 73% of those with
thyroiditis also had diagnoses of PH.
Discussion
We demonstrate that one can repurpose previously geno-
typed samples linked to longitudinal EMR-derived data to
identify variants associated with a disease unrelated to
the original study hypotheses. In this study, we found
that 9q22 variants near FOXE1, also known as thyroid
transcription factor 2, are associated with PH in a
European-American population. This association was ob-
served independently with consistent effect size and
direction in each of the five sites from which samples
were derived, and it was independently verified in a
sixth EMR-derived population. Importantly, neither the
primary analysis nor the replication set required new gen-
otyping. Furthermore, the phenotype algorithm devel-
oped at a single site proved portable to four other institu-
tions and used only patient information derived as a
byproduct of normal clinical care. PheWAS of this region
suggests that these variants near FOXE1 are specifically
associated with Hashimoto thyroiditis and might be
associated with other thyroid conditions as well. These
results support a growing body of evidence that DNA-
linked EMRs might represent a powerful and cost-effec-
tive platform for future genomic investigation of many
phenotypes.
FOXE1 is an intronless gene. These variants near
FOXE1 have been previously associated with increased
risk for both papillary and follicular thyroid cancer.23
Of note, the rs965513 minor allele has been shown to
confer risk of thyroid cancer in this and prior studies,23
whereas the major allele confers risk to PH, as demon-
strated in this study. Some retrospective studies have sug-
gested an association between thyroiditis and thyroidan Genetics 89, 529–542, October 7, 2011 535
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536 The American Journal of Human Genetics 89, 529–542, Octobercancer, although the primary process is unclear.45,46 In
addition, higher TSH levels have been associated with
an increased incidence of thyroid cancer and advanced-
stage disease.47 Mutations in the coding region of
FOXE1 have also been associated with a rare form of syn-
dromic congenital hypothyroidism (Bamforth-Lazarus
syndrome: hypothyroidism, cleft palate, choanal atresia,
spiky hair [MIM 241850]),11 and cleft lip with or without
cleft palate and isolated cleft palate).48,49 These observa-
tional data from humans are consistent with model
systems showing that mice null for Foxe1 also exhibit
cleft palate and thyroid abnormalities.50 Moreover, prior
research has demonstrated that the FOXE1 variants iden-
tified in this study are also associated with lower serum
TSH levels in euthyroid individuals.23,51 FOXE1 also
has a polymorphic polyalanine stretch; variations in
the length of this polyalanine stretch have been shown
to result in variable transcription activity and risk of
congenital hypothyroidism resulting from thyroid
dysgenesis.52,53
FOXE1 is expressed during embryologic development
and plays an important role in morphogenesis of the
thyroid gland.54 Targeted disruption of Foxe1 in mice
leads to a sublingual thyroid or thyroid agenesis, and
patients with biallelic mutations are usually athyr-
eotic.55 Later in development and in adults, the FOXE1
gene product binds to response elements in the pro-
moter regions of the thyroglobulin (TG) and thyroid
peroxidase (TPO [MIM 606765]) genes and helps regulate
transcription of both proteins.56,57 The majority of PH
patients exhibit autoantibodies to thyroglobulin or
thyroid peroxidase,58 suggesting a possible link between a
change in regulation of TPO production and the forma-
tion of autoantibodies.
The strongest association in the PheWAS analysis was
hypothyroidism with an odds ratio nearly identical to
that of the curated case-control population in the primary
analysis, providing further validation of the PheWAS
method. PheWAS also supports an association with
thyroiditis, of which themost common form is Hashimoto
thyroiditis. The relatively more significant odds ratio for
those individuals with thyroiditis (0.58 versus 0.74)
suggests that the underlying pathology for FOXE1-related
risk of PH may be thyroiditis, especially when one
considers that the underlying cause of most PH is Hashi-
moto thyroiditis. Although other variants, such as CTLA4
and PTPN22, that confer risk for PH have been associated
with Graves disease,19 rs965513 was not. B-12-deficiency
anemia occurs more commonly in individuals and family
members with PH;59 however, the PheWAS associations
of rs965513 with B-12-deficiency anemia and PH were
inversely related, despite the fact that patients with hy-
pothyroidism were more likely to have B-12-deficiency
anemia in the eMERGE population (OR ¼ 4.8). Thus, these
results suggest that other genetic or clinical factors might
mediate the clinical and familial associations of PH with
B-12-deficiency anemia.7, 2011
Figure 3. Manhattan Plot of Phenome-wide Association Study for rs965513
The PheWAS considered 866 phenotypes via single SNP tests of association (logistic regression) adjusted for age and sex. The red line
indicates Bonferroni significance for these associations, p ¼ 5.8 3 105. The blue line indicates p ¼ 0.05. For labeled associations, the
dot size varies by the magnitude of the odds ratio. For purposes of display, we normalized all odds ratios by taking the multiplicative
absolute value such that all values were greater than 1 (e.g., an odds ratio of 0.5 becomes 2).The association of FOXE1 variants with at least two
structures derived from the embryonal foregut suggests
that disorders of other foregut-derived adult organs might
also display a genetic association with this locus. These
organs include the pharynx; mouth and palate; thymus
gland and related lymphoid tissue; esophagus, stomach,
hepatic cells, and bile cannaliculi; gall bladder and com-
mon bile duct; pancreatic acinar and island cells; and
upper duodenum.60 The association between these vari-
ants and thyroid cancer as well as, possibly, several cancers
of lymphoid and salivary glands suggests that FOXE1 plays
a role in the development and differentiation of these
tissues. Further investigation of the PheWAS findings high-
lighted in this analysis will require future study with care-
fully defined phenotypes.
Previous genetics studies of PH have included family-
based linkage and association studies.19 These studies
have implicated several chromosomal regions61 and
candidate genes,62 but none have localized a gene linked
to PH. Interestingly, the HLA region, which is a can-
didate region in light of the autoimmune basis of PH,The Americhas not been consistently linked to autoimmune thyroid
disease63 and was not associated with PH in this data set
(Table S5 in the Supplemental Data available online).
The lack of consistent findings across prior studies could
be due to a variety of factors, such as insufficient statistical
power, unaccounted-for environmental influences, ge-
netic heterogeneity, and phenotypic heterogeneity.
Indeed, case definitions differed greatly across studies.
Some studies included both Graves disease and autoim-
mune hypothyroidism in their case definition, whereas
others did not. The present study excluded Graves disease
from PH case definition, and the fact that Graves disease
was not associated with rs965513 by the PheWAS analysis
supports this exclusion. Previous candidate-gene studies
have shown associations with hypothyroidism and
PTPN22 rs2476601;17 this association was observed in
this analysis (controls: p ¼ 5.0 3 104, OR ¼ 1.29; non-
TSH controls: p ¼ 4.3 3 104, OR ¼ 1.30), albeit not at
genome-wide significance. CTLA4 rs3087243 has also
been associated with hypothyroidism,16 but no associa-
tions with CTLA4 were detected here; however, this SNPan Journal of Human Genetics 89, 529–542, October 7, 2011 537
Table 5. Phenotypes Associated with rs965513 Near FOXE1 in PheWAS Analysis
Associated Phenotype n
Primary PheWAS PheWAS Adjusted for PH
Odds Ratio (95% CI) p Value Odds Ratio (95% CI) p Value
Hypothyroidism 2108 0.76 (0.70–0.81) 2.7 3 1013 – –
Thyroiditis 185 0.58 (0.46–0.74) 1.4 3 105 0.52 (0.33–0.82) 4.8 3 103
Nontoxic nodular goiter 605 0.76 (0.67–0.86) 3.1 3 105 0.78 (0.66–0.93) 4.0 3 103
Nutritional deficiency anemiaa 332 1.41 (1.20–1.66) 3.7 3 105 1.44 (1.23–1.70) 9.7 3 106
Nontoxic multinodular goiter 319 0.69 (0.57–0.82) 3.9 3 105 0.75 (0.59–0.96) 0.02
Hashimoto’s thyroiditis 127 0.58 (0.43–0.77) 2.5 3 104 0.51 (0.27–0.97) 0.04
Abnormal thyroid function studies 295 0.71 (0.59–0.85) 2.8 3 104 0.77 (0.64–0.93) 7.0 3 103
Thyrotoxicosis 354 0.76 (0.64–0.90) 1.5 3 103 0.71 (0.53–0.95) 0.02
Deficiency of B-vitamins 393 1.26 (1.09–1.46) 2.1 3 103 1.30 (1.13–1.51) 3.9 3 104
Pernicious or B12-deficiency anemia 182 1.40 (1.13–1.74) 2.1 3 103 1.45 (1.17–1.80) 7.7 3 104
Atrial flutter 486 1.25 (1.08–1.45) 3.1 3 103 1.29 (1.12–1.50) 6.9 3 104
Hemorrhoids 2916 0.90 (0.84–0.97) 4.4 3 103 0.91 (0.85–0.98) 0.01
Simple goiter 389 0.80 (0.68–0.93) 5.1 3 103 0.94 (0.77–1.16) 0.57
Thyroid cancer 96 1.29 (0.96–1.72) 0.09 1.55 (1.16–2.09) 3.5 3 103
Iatrogenic hypothyroidismb 197 0.85 (0.69–1.06) 0.15 – –
Benign thyroid neoplasm 55 1.23 (0.84–1.81) 0.29 1.36 (0.93–1.99) 0.11
Graves disease 106 1.03 (0.78–1.38) 0.82 0.86 (0.44–1.67) 0.65
All associations with p< 53 103, as well as other thyroid-related phenotypes, are shown. Bonferroni significance for these associations are p¼ 0.05/866¼ 5.83
105.
a Includes B12, folate, and protein-deficiency anemias as well as other unspecified nutritional anemias. It excludes iron-deficiency anemia.
b Includes hypothyroidism resulting from surgery or radioiodine ablation.and others in strong LD with it are not assayed on the
Illumina 660-W BeadChip.
The results of this study demonstrate the successful reuse
of EMR-linked genotype data as a discovery resource. This
approach could support investigation of many diseases
because individuals commonly experience many clinically
important health conditions over the course of their
lifetime. As the number of EMR-linked DNA biobanks
increase, the possibility for numerous in silico genetic
analyses also increases. The EMR contains a longitudinal
record of disease, response to treatment, and evolution of
care—all possible targets for future genomic and pharma-
cogenomic association studies. Moreover, as EMRs accrue
additional phenotypic information through more wide-
spread adoption and use in routine clinical care, the utility
of such resources will grow.
A rate-limiting step toward EMR-based genetic associa-
tion studies is identification of relevant case and control
populations. Often, this involves either manual review of
patient charts or creation of phenotype algorithms that
incorporate a combination of techniques such as queries
of billing code data, laboratory values, and natural
language processing to interrogate data found in clinical
notes. The phenotype selection logic developed at one
site was successfully deployed with similar performance538 The American Journal of Human Genetics 89, 529–542, Octoberat five different sites with different EMR systems. One
site, the Mayo Clinic, noted a lower positive predictive
value for PH case identification. Algorithm classification
errors largely resulted from exclusionary events predating
electronic records (e.g., thyroidectomy in the 1940s) or
from events occurring at outside medical facilities (e.g.,
military personnel treated at the VA). More advanced
application of natural language processing might im-
prove the ability to detect such non-coded data. Devel-
oping libraries of phenotype selection algorithms is a
goal of the eMERGE network; a repository of phenotype
selection algorithms is available online (see Web
Resources).
Several limitations of this study deserve comment.
Application of phenotype selection logic requires robust
EMR systems capable of efficient data querying so that
cohorts of patients matching specific criteria can be identi-
fied. Although our specific phenotype selection logic per-
formed well for PH at these five sites, similar efforts will
be needed if new selection logics uniquely suited for the
study of other traits are to be developed. Our ascertain-
ment and evaluation of phenotype characterization for
cases and controls was limited to information available
in the medical record; thus, some of our patients might
have secondary causes for hypothyroidism, but these7, 2011
might not have been recognized by their treating physi-
cians. Given that PH accounts for the vast majority of
hypothyroid cases, we suspect that this misclassification
bias is low. Although we asked reviewers validating our
algorithm to exclude patients having only subclinical
hypothyroidism from our analysis, it is possible that
some of these patients had subclinical hypothyroidism
instead of overt PH. However, patients with subclinical
hypothyroidism often develop overt PH, especially in the
absence of secondary causes (e.g., radiation exposure)
specifically excluded in this study.64,65 Although we did
not have formal iodine measurement available in our
patients, the United States has supplemented dietary
iodine intake through iodinated salt since 1920, making
iodine-related hypothyroidism rare.66,67 Finally, our repli-
cation set was about a decade younger than the discovery
set. However, because all control subjects had normal
TSH values and absence of thyroid replacement medica-
tions in their medication lists, we believe that false-
negative controls were rare.
In summary, this study demonstrates several notable
findings. First, the study identifies and replicates variants
near FOXE1 as genetic risk factors for PH. Second, it quan-
tifies the portability of automated selection logic applied
across five health centers with heterogeneous data models,
EMR systems, and local practice patterns. Third, this study
demonstrates the utility of EMR data for finding multiple
clinically relevant phenotypes, based on the co-occurrence
of multiple diseases in individuals. Finally, this study
shows the potential for discovery of previously unknown
genetic associations through the reuse of existing genomic
data linked to clinical findings recorded in EMRs.Supplemental Data
Supplemental Data include eight figures and six tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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